DGAP-News: SYGNIS Pharma AG: EDISON values SYGNIS at 37.5 million euros
(firmenpresse) - DGAP-News: SYGNIS Pharma AG / Key word(s): Study
SYGNIS Pharma AG: EDISON values SYGNIS at 37.5 million euros
10.07.2013 / 16:17
---------------------------------------------------------------------
Press Release
EDISON values SYGNIS at 37.5 million euros
- This valuation amply exceeds the current market quotation and ascribes
the shares a potential growth rate of more than 50%.
- EDISON base their analysis on three of SYGNIS' current products,
including QualiPhi, which was licensed to Qiagen and will be launched
in the third quarter of this year.
Madrid/Heidelberg, 10 July 2013 - EDISON, international analysts who
specialize in listed companies of the industry, recently published a
thorough analysis of the biotech company SYGNIS Pharma AG (Frankfurt: LIO1;
ISIN: DE000A1RFM03; Prime Standard segment of the German Stock Exchange).
As a result of EDISON's analysis of the company, the objective value of
SYGNIS, taking into account the launch of QualiPhi in the third quarter of
2013 - licensed by Qiagen - as well as the license of two further products
this year: PrimPol and Double Switch, would reach 37.5 million euros.
SYGNIS shares were listed at 2.63 euros last Tuesday at Frankfurt's stock
market, with capitalization close to 25 million euros. Therefore, EDISON's
estimations place the value of the shares at a potential increase of more
than 50% for its shareholders this year.
In order to undertake the analysis of the share value of SYGNIS, EDISON
focused on the predicted income of three products: QualiPhi, PrimPol and
Double Switch. Meanwhile, EDISON have not considered any additional
products the company has been developing (DNA repair kit), thus the income
assumptions can be considered conservative.
QUALIPHI(R), is an improved version of DNA Polymerase Phi 29. It was
generated in Professor Margarita Salas' lab, with the collaboration of
Professor Luis Blanco, in the CSIC. Using this as a starting point, the
X-POL team (GENETRIX Group), known today as SYGNIS, developed a product of
unique characteristics, focused on isothermal DNA amplification, which was
licensed to Qiagen in July 2012. The commercialization of this product will
start in the third quarter of 2013.
PrimPol is a new enzyme with the characteristics of a primase (it does not
need random primers to initiate the process) and a polymerase with elevated
proofreading capacity and high processivity, making it an optimal tool not
only for DNA amplification, but also for simplifying some technical aspects
of RNA amplification.
DoubleSwitch is a cellular technology that identifies and quantifies
interactions between proteins in a cell. Knowledge about the mechanism in
which proteins interact is particularly relevant not only in proteomics, a
field of growing interest, but also to develop personalized drugs.
About SYGNIS Pharma AG: www.sygnis.de
After the merger in 2012 between X-Pol Biotech, specialising in DNA
amplification and sequencing, and SYGNIS Pharma AG, listed in the German
Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03),
SYGNIS' new mission is to develop and distribute technologies and products
from X-Pol, which has a commercial product in the DNA amplification
segment, QualiPhi(R) and is currently developing other products in the
field of Next Generation Sequencing.
For further information please contact:
SYGNIS Pharma AG
Pilar de la Huerta
CEO/CFOTel: +34-918063089
Email: pdelahuerta(at)sygnis.es
# # # Disclaimer:
Some statements included in this press release, relating neither to proven
financial results nor to other historical data, should be viewed as
forward-looking, i.e. not definitive. Such statements are mainly
predictions of future results, trends, plans or goals. They should not be
considered to be total guarantees since given their very nature, they are
subject to known and unknown risks, as well as to aspects beyond human
control, and can be affected by other factors as a consequence of which the
actual results, plans and goals of SYGNIS Pharma AG may deviate greatly
from the established conclusions or implied predictions contained in such
statements. SYGNIS does not undertake to publicly update or revise said
statements in light of new information or future results or for any other
reason. # # #
End of Corporate News
---------------------------------------------------------------------
10.07.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: SYGNIS Pharma AG
Im Neuenheimer Feld 515
69120 Heidelberg
Germany
Phone: 06221 454-6
Fax: 06221 454-700
E-mail: contact(at)sygnis.de
Internet: www.sygnis.de
ISIN: DE000A1RFM03
WKN: A1RFM0
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
220667 10.07.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 10.07.2013 - 16:17 Uhr
Sprache: Deutsch
News-ID 277191
Anzahl Zeichen: 7058
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 249 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: SYGNIS Pharma AG: EDISON values SYGNIS at 37.5 million euros"
steht unter der journalistisch-redaktionellen Verantwortung von
SYGNIS Pharma AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
